Consumer drug advertising remains corporate benefitmanagers’ favorite culprit in rising prescription drug costs, according to anArxcel survey. Forty-five percent cited DTC as the top cause of rising costs,compared to 36% in 2006 and 30% in 2005. R&D costs placed second, with 24%,and an aging population ranked third, at 17%.